Compare Medpace Holdings Inc (MEDP) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs United Airlines Holdings Inc — how do they compare? Medpace Holdings Inc trades at $615.1 (market cap $16.82B), while United Airlines Holdings Inc trades at $105.51 (market cap $34.87B). The key difference: United Airlines Holdings Inc is far larger — about 2.1× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and United Airlines Holdings Inc for 46 Days on average.
| MEDP | UAL | |
|---|---|---|
Market Cap | $16.82B | $34.87B |
Volume | 223,093 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $630.19 | $136.11 |
52-Week Low | $393.42 | $85.21 |
Typical Hold Time | 14 Days | 46 Days |
Enterprise Value | $16.44B | $51.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
United Airlines (UAL) trades at $110.17, down 1.53% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.06, net income margin of 5.56%, and three consecutive quarterly EPS beats. Recent news highlights aggressive customer acquisition tactics targeting Delta's elite travelers with status-match offers and Starlink WiFi advantages.
Outlook remains positive given analyst consensus of $158.10 price target and 66% buy ratings, but risks include rising fuel costs, labor expenses, and competitive pressures. Earnings growth and market share gains are key catalysts, though near-term volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
